• Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm
• Offer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024
• Option for Lantheus to invest a further A$7.5m within 6 months on the same terms
• Lantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement
240620-Radiopharm-Receives-Strategic-Investment-for-up-to-A18-million
